Sutro Biopharma, Inc. (STRO) Stock Score, Valuation & Financial Research
Sutro Biopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for STRO
Sutro Biopharma, Inc. currently has a Wall Street Score of 21/100. The stored market price is $16.56. Its financial score is 23/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sutro Biopharma, Inc. does
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strateg
STRO financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $16.56
- Market capitalization:
- $160.3M
- Revenue:
- $99.6M
- Net income:
- $-153.6M
- Free cash flow:
- $-178.9M
- Cash:
- $73.7M
- Total debt:
- $13.6M
- EPS:
- -22.49
- Financial score:
- 23/100
- Valuation score:
- 0/100
- Revenue score:
- 4/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-178.9M, showing cash burn in the current stored period.
- The balance sheet shows $73.7M of cash versus $13.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research STRO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.